[go: up one dir, main page]

Phelan et al., 1987 - Google Patents

HTLV-III/LAV particle-associated proteins: I. Virus purification, inactivation and basic characterization

Phelan et al., 1987

Document ID
3096520292390648142
Author
Phelan M
Hall J
Wells M
Kowalski M
Vujcic L
Quitman Jr G
Epstein J
Publication year
Publication venue
Proteins: Structure and Function

External Links

Snippet

Human T-lymphotropic virus type III/lymphadenopathy virus (HTLV-III/LAV) is the etiologic agent of acquired immunodeficiency syndrome (AIDS), 1-2 although cofactors may play a significant role in disease expression. 5 Changes in social behavior may reduce the rate of …
Continue reading at link.springer.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Similar Documents

Publication Publication Date Title
Henderson et al. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III
Chertova et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus
Robey et al. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
Grant et al. Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas
Kirkpatrick Transfer factors: identification of conserved sequences in transfer factor molecules
Fultz et al. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome
DI MARZO VERONESE et al. Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15
Montagnier et al. A new type of retrovirus isolated from patients presenting with lymphadenopathy and acquired immune deficiency syndrome: structural and antigenic relatedness with equine infectious anaemia virus
US6420141B1 (en) Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids
Payne et al. Course and extent of variation of equine infectious anemia virus during parallel persistent infections
Gaddis et al. Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions
Casey et al. Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24
Pinto et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
Ranki et al. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins
CA2072351A1 (en) Hiv-1 core protein fragments
Nara et al. The biology of human immunodeficiency virus‐1 IIIB infection in the chimpanzee: in vivo and in vitro correlations
Cabradilla et al. Serodiagnosis of antibodies to the human AIDS retrovirus with a bacterially synthesized env polypeptide
Masemola et al. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa
EHRLICH et al. Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24)
Beretta et al. Human Immunodeficiency Virus Type 1 (HIV-l)-Seronegative Injection Drug Users at Risk for HIV Exposure Have Antibodies to HLA Class I Antigens and T Cells Specific for HIV Envelope
Opi et al. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants
Dow et al. Lymphocytic choriomeningitis virus infection yields overlapping CD4+ and CD8+ T-cell responses
De Francesco et al. HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor
Shankar et al. Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes
Phelan et al. HTLV-III/LAV particle-associated proteins: I. Virus purification, inactivation and basic characterization